Atherosclerosis is recognized at present as a chronic metabolic disease of the arteries that leads to multifocal plaque development. Previous studies have reported that acid fibroblast growth factor (aFGF) is a critical therapeutic regulator in numerous chronic metabolic disorders. However, there is currently no direct evidence indicating whether aFGF serves a therapeutic role in atherosclerosis. In the present study, the role of aFGF in atherosclerotic lesion development was investigated by examining high-fat diet (HFD)-fed apolipoprotein E (ApoE) -/mice and parenteral administration of aFGF. Increased expression of aFGF and peroxisome proliferator-activated receptor α (PPARα) was observed during atherosclerotic lesion development. The parenteral delivery of aFGF facilitated the progression of atherosclerosis without altering serum lipid expression levels in HFD-fed ApoE -/mice. Furthermore, it was demonstrated that aFGF increased the expression of PPARα and inflammatory cytokines. The present results provided evidence that aFGF accelerates the progression of atherosclerosis and suggested that aFGF may be a potential therapeutic target for the prevention of atherosclerosis development.
Introduction
Acid fibroblast growth factor 1 (aFGF) is a mitogenic factor that has been associated with peroxisome proliferator-activated receptors (PPARs) (1, 2) , has been reported to be a critical therapeutic regulator in numerous chronic metabolic disorders. aFGF-knockout mice develop insulin resistance when stressed with a high-fat diet (HFD), suggesting that aFGF has a beneficial effect on nutrient homeostasis (1) . aFGF additionally has therapeutic potential for the treatment of non-alcoholic fatty liver disease (2) .
Atherosclerosis is the principal cause of coronary artery disease, and is therefore a principal cause of mortality and morbidity globally (3) . It is noteworthy that atherosclerosis is additionally recognized as a lipid-driven chronic metabolic disease (4) . Previous studies have reported increased aFGF expression in atherosclerotic plaques in human (5) and swine (6) models. However, there is no direct evidence indicating whether aFGF serves a therapeutic role in atherosclerosis. Recent studies demonstrated that PPARα is a key regulator of atherosclerosis and is involved in HFD-induced atherosclerosis in apolipoprotein E (ApoE)-null mice (7) .
In the present study, the role of increased aFGF and PPARα expression in atherosclerotic lesion development was verified by examining ApoE-null mice. Furthermore, it was identified that parenteral delivery of aFGF increased the expression of PPARα, the induction of inflammatory cytokines, and the subsequent development of atherosclerotic plaques.
Materials and methods
Animal experiments. The protocols used for all animal studies were approved by the Wenzhou Medical University Animal Policy and Welfare Committee (Wenzhou, China; approval no. wydw2014-0058). Male ApoE -/mice (n=28; 18-20 g; 8 weeks old) with a C57BL/6 background were purchased from Beijing HFK Bioscience Co., Ltd., (Beijing, China). Mice were housed at 22±2.0˚C with 50±5% humidity in a 12 h light/dark cycle with free access to food and water. To induce atherosclerosis, the mice were fed a HFD containing 60% kcal from fat, 20% kcal from protein and 20% kcal from carbohydrate (MediScience Diets Co., Ltd., Yangzhou, China; cat. no. MD12033) for 16 weeks (n=7; ApoE HFD), while the control animals were fed a normal-fat diet (NFD) containing Acid fibroblast growth factor facilitates the progression of atherosclerotic plaques regardless of alterations in serum lipid expression levels in HFD-fed ApoE -/mice 10% kcal from fat, 20% kcal from protein and 70% kcal from carbohydrate (MediScience Diets Co., Ltd.; cat. no. MD12031; n=7; ApoE NFD).
In the second set of experiments, mice that were fed a HFD for 8 weeks were randomly divided into the following two groups: ApoE HFD treated with vehicle via intraperitoneal (IP) injection (PBS for 8 weeks; n=7) and ApoE HFD treated with aFGF (Key Laboratory of Biotechnology and Pharmaceutical Engineering, Zhejiang, China) via IP injection [0.5 mg/kg/2 days for 8 weeks, as described in a previous paper (2); n=7]. The mice were sacrificed by increasing CO 2 inhalation, in accordance with Schedule 1 of the Animals (Scientific Procedures) Act (1986) as previously described (8) , and blood was collected into a syringe containing 4% trisodium citrate (1:10, v/v) via cardiac puncture. Arterial tissues were fixed in 4% paraformaldehyde at a room temperature for 24 h and embedded in optimum cutting temperature compound. Tissues were snap-frozen in liquid nitrogen and serial 10 µm-thick cryosections from the middle portion of the tissues were collected for gene and protein expression analysis.
Measurement of the expression levels of serum lipids and biochemical indicators.
The expression level of serum lipids was measured using lipid-specific biochemical kits [Nanjing Jiancheng Bioengineering Institute, Nanjing, China; cat. no. A110-1 for triglycerides (TG); cat. no. A113-1 for low-density lipoprotein (LDL); cat. no. A112-1 for high density lipoprotein (HDL); and cat. no. F002-1 for total cholesterol (TC)].
Immunofluorescence staining. The expression of aFGF and PPARα was measured by immunofluorescence staining. Frozen sections were used for immunofluorescence analysis. The slides were blocked using 1% bovine serum albumin for 30 min at room temperature and incubated overnight at 4˚C with an aFGF antibody (1:200; cat. no. ab169748) or a PPARα antibody (1:200; cat. no. ab119416). A tetramethylrhodamine-conjugated secondary antibody (1:200; cat. no. ab6786; all Abcam, Cambridge, UK) was used for detection at 4˚C for 1 h. The slides were additionally stained with DAPI at 4˚C for 5 min (5 mg/ml; Beyotime Institute of Biotechnology, Haimen, China; cat. no. C1005). Slides were viewed under a fluorescence microscope (magnification, x200). The images were analyzed with Image-Pro Plus (version 6.0 Media Cybernetics, Inc., Rockville, MD, USA).
Histology and analysis of atherosclerotic lesions.
Atherosclerotic lesions were measured as described in a previous paper (9) . The whole aorta, including the aortic arch and the thoracic and abdominal segments, was dissected, gently cleaned of adventitial tissue and stained with Oil Red O at room temperature for 15 min (5 mg/ml; Nanjing Jiancheng Bioengineering Institute; cat. no. D027). The surface lesion area was quantified with ImageJ software (version 1.6.2; National Institutes of Health, Bethesda, MD, USA). To measure lesions in the aortic root, the heart and proximal aorta were excised, and the apex and lower half of the ventricles were removed and stained with Oil Red O for 15 min (5 mg/ml) at room temperature. The surface lesion area was quantified with ImageJ software.
Five frozen sections were also stained with hematoxylin and eosin at room temperature (eosin for 2 min and hematoxylin for 5 min) for histopathological observation.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated from arterial tissues using TRIzol ® (cat. no. 15596026). RT and qPCR were performed using a two-step Moloney Murine Leukemia Virus kit (cat. no. 28025013) and a Platinum SYBR Green qPCR SuperMix-uracil DNA glycosylase kit (cat. no. 11733046; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in an Eppendorf Mastercycler ep RealPlex detection system (Eppendorf, Hamburg, Germany). PCR quantification was performed using the 2 -ΔΔCq method (10) . Primers were obtained from Thermo Fisher Scientific, Inc. The primer sequences are listed in Table I . mRNA expression levels of the target genes were normalized to β-actin.
Statistical analysis. Data are presented as the mean ± standard error of the mean. Differences between the groups were determined using the Student's t-test, as appropriate, in GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Increased expression of aFGF and PPARα in the aortas of HFD-fed ApoE -/mice. A classical paradigm of the HFD-induced ApoE -/atherosclerosis model is the alteration of serum lipid expression levels, as elevated LDL has been demonstrated to be strongly associated with the development of atherosclerosis (8) . ApoE -/mice fed a HFD exhibited significantly increased serum expression levels of TG, TC and LDL ( Fig. 1A-C ; P<0.001) and significantly reduced expression levels of high-density lipoprotein (HDL) compared with control mice fed an NFD ( Fig. 1D; P<0 .05).
The aortic tissues from the mice were subsequently assessed by immunofluorescence staining to determine whether aFGF and PPARα are involved in the progression of atherosclerotic plaques. The expression levels of aFGF ( Fig. 2A) and PPARα (Fig. 2B) were increased in HFD-fed mice compared with NFD-fed mice in atherosclerotic lesions of the aortic root and aorta. The mRNA isolated from aortic tissues confirmed that the expression levels of aFGF were increased in HFD-fed mice (Fig. 2C) . These increased expression levels of aFGF and PPARα corresponded with morphological alterations in HFD-fed ApoE -/mice, including an augmented atherosclerotic plaque lesion area in the aortic root ( Fig. 2D ) and aorta ( Fig. 2E ) compared with ApoE NFD mice, reinforcing the hypothesis that there is a positive association between atherosclerotic plaque development and increased aFGF and PPARα expression levels.
Treatment with aFGF aggravates atherosclerotic plaque development in HFD-fed ApoE -/mice. The second set of experiments aimed to determine whether parenteral administration of aFGF was associated with HFD-induced atherosclerotic development. Oil Red O staining of the entire aorta was performed in the en face preparation and of the aortic root to measure the severity of these lesions. Notably, the present results demonstrated a significantly increased lesion area in ApoE HFD mice treated with aFGF compared with ApoE HFD mice treated with vehicle in the entire aorta ( Fig. 3A and B ) and the aortic root ( Fig. 3C and D ). An additional assessment by hematoxylin and eosin staining demonstrated that the plaque areas in the aortic root of aFGF-treated mice were aggravated in comparison with vehicle-treated HFD-fed mice (Fig. 3E) . The present results indicated that the administration of aFGF accelerated the progression of atherosclerotic plaques.
Treatment of mice with aFGF does not affect the expression levels of serum lipids. The present study additionally aimed to determine whether the administration of aFGF alters serum lipid expression levels. Notably, the treatment of mice with aFGF for 8 weeks did not affect the expression levels of serum lipids, including TG (Fig. 4A) , TC (Fig. 4B) , LDL (Fig. 4C ) and HDL (Fig. 4D) , compared with vehicle-treated HFD-fed mice, suggesting that the aFGF-facilitated progression of atherosclerosis may be trigged or maintained via mechanisms that are parallel to or independent of hyperlipidaemia.
Administration of aFGF increases the mRNA expression levels of PPARα and inflammatory factors in HFD-fed ApoE -/mice.
It has been established that PPARα (7) and inflammation (11) contribute to atherosclerotic lesions. To determine whether the aggravating effect of aFGF on atherogenesis is associated with PPARα and its downstream inflammatory factors (12) , the mRNA expression levels of PPARα and associated inflammatory factors were assessed, including interleukin (IL)-1β and IL-6, in vivo. The present data demonstrated that the mRNA expression levels of PPARα (Fig. 4E ), IL-6 ( Fig. 4F ) and IL-1β ( Fig. 4G ) all significantly increased when atherosclerotic mice were treated with aFGF (P<0.05).
Discussion
Atherosclerosis is a systemic, chronic metabolic disease of the principal arteries. The formation and progression of atherosclerotic plaques involves hyperlipidemia, inflammation, foam cell formation, smooth muscle cell proliferation and increased matrix synthesis (13) . In the present study, it was observed that atherosclerosis was associated with elevated aFGF expression levels, consistent with a previous report (14) .
The FGF family, which contains 22 members in mammals, has diverse biological functions in the progression of atherosclerotic plaques (15) . Basic (b)FGF has been detected in human atherosclerotic plaques (16) , and increased expression of bFGF is associated with carotid atherosclerotic plaque instability (17) . By contrast, the depletion of FGF21 in ApoE -/mice results in a markedly increased exacerbation of atherosclerosis, which may be reversed by replenishment with exogenous mouse recombinant FGF21 (18) . The key present results suggested that aFGF facilitated the progression of atherosclerosis regardless of alterations in serum lipid expression levels, which is inconsistent with the protective role of aFGF in other chronic metabolic diseases (1, 2) . However, FGFs exert their biological effects by interacting with and activating FGF receptors (FGFRs) (14) . The present results are consistent with those reported by Raj et al (14) , who demonstrated Table I . Sequences of primers for the reverse transcription quantitative polymerase chain reaction assay used in the present study. Gene that the inhibition of FGFR tyrosine kinase activity reduced atherosclerotic plaque development, suggesting that an active aFGF/FGFR1 signaling system promotes atherosclerosis development.
Tordjman et al (7) demonstrated that PPARα deficiency reduces insulin resistance and atherosclerosis in ApoE-null mice. The present results additionally demonstrated that the expression levels of PPARα were increased in aortic atherosclerotic lesions in HFD-fed mice. Although certain evidence suggests a role for aFGF in PPAR-γ-associated chronic metabolic disease (1, 2) , the association between aFGF and PPARα remains unknown. The present results demonstrated that treatment with aFGF increased the mRNA expression levels of PPARα and inflammatory factors. Therefore, the present results suggested that aFGF may be the upstream regulator of PPARα and its associated inflammation, which requires validation in future studies.
In conclusion, the present results demonstrated that aFGF promotes the progression of atherosclerotic plaques via PPARα and inflammatory mechanisms, which occurs independently from alterations in serum lipid expression levels. The present results suggested that targeting aFGF may have therapeutic potential for preventing atherosclerosis.
